Advances in Hematopoietic Stem Cell Transplantation: A Review of Recent Developments and Challenges

Abstract

Hematopoietic Stem Cell Transplantation (HSCT) remains a cornerstone therapy for a wide spectrum of hematologic malignancies, congenital immunodeficiencies, and inherited metabolic disorders. Over the past decade, significant scientific and clinical advancements have reshaped HSCT, extending its curative potential while mitigating associated risks. Progress in donor selection, including high-resolution HLA typing and the widespread use of haploidentical donors, has expanded global transplant accessibility. Innovations in conditioning regimens such as reduced-intensity approaches and antibody-drug conjugates have optimized the balance between efficacy and toxicity, enabling safer procedures for older and medically fragile patients. Parallel developments in graft engineering, immune modulation, and cellular therapy integration have transformed post-transplant outcomes, particularly through the introduction of post-transplant cyclophosphamide, regulatory T-cell infusion, and NK-cell–based strategies to control Graft-Versus-Host Disease (GVHD). The emergence of gene-editing technologies, including CRISPR/Cas9-mediated autologous transplantation, has further broadened the therapeutic frontier for genetic and hematologic disorders. Advances in infection prophylaxis, supportive care, and long-term survivorship management continue to improve quality of life and survival rates. Despite these achievements, persistent challenges such as chronic GVHD, relapse, donor scarcity, and socioeconomic disparities underscore the need for continued innovation. This review synthesizes contemporary breakthroughs in HSCT biology, technology, and clinical application, critically examines unresolved barriers, and highlights future directions, including Artificial Intelligence (AI)-driven predictive analytics, universal donor platforms, and equitable global access strategies.